Alaproclate (developmental code name GEA-654) is a drug that was being developed as an antidepressant by the Swedish pharmaceutical company Astra AB (now AstraZeneca) in the 1970s. It acts as a selective serotonin reuptake inhibitor (SSRI), and along with zimelidine and indalpine, was one of the first of its kind. Development was discontinued due to the observation of liver complications in rodent studies. In addition to its SSRI properties, alaproclate has been found to act as a non-competitive NMDA receptor antagonist, but does not have discriminative stimulus properties similar to phencyclidine.
Attributes | Values |
---|---|
rdf:type | |
rdfs:label |
|
rdfs:comment |
|
foaf:depiction | |
dcterms:subject | |
Wikipage page ID |
|
Wikipage revision ID |
|
Link from a Wikipage to another Wikipage |
|
Link from a Wikipage to an external page | |
sameAs | |
dbp:wikiPageUsesTemplate | |
thumbnail | |
ATC suffix |
|
ATC prefix |
|
c |
|
CAS number |
|
ChEMBL |
|
ChemSpiderID |
|
Cl |
|
H |
|
IUPAC name |
|
KEGG |
|
legal status |
|
n |
|
O |
|
PubChem |
|
routes of administration |
|
SMILES |
|
StdInChI |
|
StdInChIKey |
|
UNII |
|
Verifiedfields |
|
verifiedrevid |
|
Watchedfields |
|
has abstract |
|
gold:hypernym | |
prov:wasDerivedFrom | |
page length (characters) of wiki page |
|
CAS number |
|
ChEMBL |
|
FDA UNII code |
|